Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
about
sameAs
Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremityPrimary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremityRegulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanismsGuidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapyConcomitant use of buffered and enteric-coated low-dose aspirin products and antisecretory drugsNSAIDs: gastroprotection or selective COX-2 inhibitor?Role of Helicobacter pylori eradication in aspirin or non-steroidal anti-inflammatory drug usersAssociation between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studiesBalancing the gastrointestinal benefits and risks of nonselective NSAIDs.The role of cyclooxygenase in gastric mucosal protectionUpper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in DenmarkPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinRisk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseasesA population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirinAdverse effects of conventional non-steroidal anti-inflammatory drugs on the upper gastrointestinal tractReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyondThe impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorThe appropriate use of proton-pump inhibitor co-therapy with non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitorsPotential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico CityHospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort studyThe David Y. Graham lecture: use of nonsteroidal antiinflammatory drugs in a COX-2 restricted environmentA prospective study of aspirin use and the risk of gastrointestinal bleeding in menAspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksDecreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974-2002.Gender differences of low-dose aspirin-associated gastroduodenal ulcer in Japanese patients.Complications of peptic ulcer disease.Ibuprofen to rofecoxib: what does it all mean and what do I do now?H(2)S-releasing aspirin protects against aspirin-induced gastric injury via reducing oxidative stress.Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies.Prevalence of gastroduodenal ulcers/erosions in patients taking low-dose aspirin with either 15 mg/day of lansoprazole or 40 mg/day of famotidine: the OITA-GF study 2.Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)Risk management of risk management: Combining proton pump inhibitors with low-dose aspirinReview article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illnessProblem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.NSAIDs and gastrointestinal complications: new clinical challenges.
P2860
Q24197472-C96485C6-1983-4F51-90AD-723690274274Q24201769-A74321B2-B867-47DB-82A6-4EA8E4788520Q26849624-261BE486-15AA-4190-986A-C6740D357250Q28166768-21ED7348-16C0-4FAA-8CE1-D89AFC79B5A9Q28168123-23A5389D-D516-455E-AD11-5B09B41781ADQ28168965-51BA04CA-A7D9-438F-B2B8-E4618098FD9DQ28182449-219D7547-2E85-4057-A164-5B21C74FF211Q28182449-D94B304A-E38E-41BE-AE19-2DEA4A9F2A87Q28191843-76719B90-ACB6-4E3D-9F2C-116DD568AD60Q28191843-A459C47B-6232-4B99-B5C8-5502B602494BQ28191932-21FDFA64-EB11-4E0C-A4AC-1E0687ABEB47Q28191932-EEED2A3C-0E33-4554-88EA-DD67CD507D65Q28192148-130FED01-E72A-486F-B09B-9AFDC217AC08Q28192383-5FFCE872-7602-495F-B203-9F4D5D8EB403Q28192383-921138EF-F7B5-4883-8A41-432C8B7980D8Q28192701-A1CA1A1F-A34B-4CCD-970D-1746594258BAQ28193996-F8AA492C-9117-4053-9DBA-6B6809896086Q28195221-08BB1A9E-3734-4605-8FC7-DD858EF8DE92Q28195221-217BD2BB-BCF3-462B-ACE3-055236F2BA4AQ28199102-A692F4D0-E7B6-40EF-A8C4-303B9687B074Q28200403-BABFFC8C-3DDF-4C3E-AD5C-D219AFC8ACB4Q28210656-BA2E5B43-24EA-4792-A6B2-FEC88336347BQ28210656-D50CBA5B-4EE4-46CC-B3C5-F640D9BDE8BCQ28217400-CE7A746E-D6CB-41BA-AE6C-EF0F0264D40EQ28218734-A3690367-CFF6-4FC1-9A88-A7E9371BD982Q28221815-51740B1B-3AE2-4DFE-A72C-B0F780DA4EDFQ28221815-BAF731AB-6E7D-4552-99F0-7B4ECDEF434BQ28222091-DAF3F8FD-AEFE-4FCB-82A2-C4C5B52BF8D5Q28222253-A276DC5B-41CD-4FB4-B861-84B1301D9BCFQ28743884-073E6A7F-4E7E-4746-92FB-92A169A56742Q28743884-68D4B2AE-38C3-44CE-BB31-F3E87AF27A4AQ30457290-AD854848-9D0A-4A7D-B855-88AE04B6470AQ30629677-B0F22F83-E1DB-45D2-900B-8869C70166A7Q30629677-D978D3B2-60E6-47F0-A7A4-5853AF027D85Q33432343-7D70F4C3-B5DB-499F-97B9-012346414C19Q33432343-E0E3B303-6C12-41EB-97B6-B3C1812E53BCQ33798895-005C9A37-E389-44ED-8299-EA3A7AA73C39Q33798895-E8F22636-CE72-40D2-AF3F-E27CEA3CE518Q34233672-0A3A4E0F-255B-4445-9C58-2DB064160B3DQ34315840-36199CCD-B70F-459C-8046-B962F8BECA22
P2860
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
@nl
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@ast
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@en
type
label
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
@nl
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@ast
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@en
altLabel
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
@en
prefLabel
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
@nl
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@ast
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@en
P2093
P2860
P1476
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin
@en
Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.
@en
P2093
Flemming Hald Steffensen
Gunnar Lauge Nielsen
Henrik Toft Sorensen
Jorgen H. Olsen
Lene Mellemkjaer
Mellemkjaer L
Nielsen GL
Steffensen FH
P2860
P304
P356
10.1016/S0002-9270(00)01040-6
10.1111/J.1572-0241.2000.02248.X
P407
P577
2000-09-01T00:00:00Z